PLEASE NOTE: Legislative Information cannot perform research, provide legal advice, or interpret Maine law. For legal assistance, please contact a qualified attorney.
An Act To Prohibit Sale or Possession of Synthetic Cannabinoids
Be it enacted by the People of the State of Maine as follows:
Sec. 1. 17-A MRSA §1101, sub-§1-A, as enacted by PL 2011, c. 428, §1 and affected by §9, is repealed.
Sec. 2. 17-A MRSA §1101, sub-§1-B, as enacted by PL 2011, c. 428, §2 and affected by §9, is repealed.
Sec. 3. 17-A MRSA §1101, sub-§3-A, as enacted by PL 2011, c. 428, §3 and affected by §9, is repealed.
Sec. 4. 17-A MRSA §1101, sub-§3-B, as enacted by PL 2011, c. 428, §4 and affected by §9, is repealed.
Sec. 5. 17-A MRSA §1102, sub-§4, ¶F, as enacted by PL 2011, c. 428, §7 and affected by §9, is repealed.
Sec. 6.  17-A MRSA §1102, sub-§4, ¶G  is enacted to read:
 
G.  Synthetic cannabinoids, including:
 
(1) Tetrahydrocannabinols that are naturally contained in a plant of the genus cannabis or a cannabis plant, as well as synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of cannabis or synthetic substances, derivatives and their isomers with similar chemical structure and pharmacological activity, including the following:
 
(a) Delta-1 cis or trans tetrahydrocannabinol and their optical isomers;
 
(b) Delta-6 cis or trans tetrahydrocannabinol and their optical isomers; or
 
(c) Delta-3,4 cis or trans tetrahydrocannabinol and their optical isomers;
 
(2) Naphthoylindoles, including any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following:
 
(a) 1-Pentyl-3-(1-naphthoyl)indole or JWH-018 or AM-678;
 
(b) 1-Butyl-3-(1-napthoyl)indole or JWH-073;
 
(c) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole or JWH-081;
 
(d) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole or JWH-200;
 
(e) 1-Propyl-2-methyl-3-(1-naphthoyl)indole or JWH-015;
 
(f) 1-Hexyl-3-(1-naphthoyl)indole or JWH-019;
 
(g) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole or JWH-122;
 
(h) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole or JWH-210;
 
(i) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole or JWH-398; or
 
(j) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole or AM-2201;
 
(3) Naphthylmethylindoles, including any compound containing a H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following:
 
(a) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane or JWH-175; or
 
(b) 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane or JWH-184;
 
(4) Naphthoylpyrroles, including any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone or JWH-307;
 
(5) Naphthylideneindenes or naphthylmethylindenes, including any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane or JWH-176;
 
(6) Phenylacetylindoles, including any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following:
 
(a) 1-(2-cyclohexylethyl)-3-(2-methoxypheylacetyl)indole or RCS-8;
 
(b) 1-Pentyl-3-(2-methoxyphenylacetyl)indole or JWH-250;
 
(c) 1-Pentyl-3-(2-methylphenylacetyl)indole or JWH-251; or
 
(d) 1-Pentyl-3-(2-chlorophenylacetyl)indole, or JWH-203;
 
(7) Cyclohexylphenols, including any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, and their isomers with similar chemical structure and pharmacological activity, including the following:
 
(a) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or CP 47,497;
 
(b) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or Cannabicyclohexanol or CP 47,497-C8 homologue; or
 
(c) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol or CP 55,490;
 
(8) Benzoylindoles, including any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following:
 
(a) 1-Pentyl-3-(4-methoxybenzoyl)indole or RCS-4;
 
(b) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole or AM-694; or
 
(c) (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y]methanone or WIN-48,098 or Pravadoline; and
 
(9) The following other unclassified synthetic cannabinoids:
 
(a) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol or HU-210;
 
(b) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol or Dexanabinol or HU-211;
 
(c) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone or WIN 55,212-2; or
 
(d) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone or XLR-11.
 
Effective 90 days following adjournment of the 126th Legislature, First Regular Session, unless otherwise indicated.